Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells-Reference-Cited by-同舟云学术

Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Published:2019-03-12 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Johanna Inez,Straetemans Trudy,Heijhuurs Sabine,Aarts-Riemens Tineke,Norell Håkan,Bongiovanni Laura,de Bruin Alain,Sebestyen Zsolt,Kuball Jürgen

Funder

ZonMw

Universiteit Utrecht

Gadeta

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0558-4.pdf

Reference40 articles.

1. Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med. 2018;10(436).

2. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494–502.

3. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206(2):463–75.

4. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109(6):2331–8.

5. Turtle CJ, Maloney DG. Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape. Expert Rev Hematol. 2016;9(8):719–21.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delta One T cells recognize AML via DNAM-1;Blood;2024-04-11

2. A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia;PLOS ONE;2024-01-30

3. γδ T cells: origin and fate, subsets, diseases and immunotherapy;Signal Transduction and Targeted Therapy;2023-11-22

4. Therapeutic avenues for γδ T cells in cancer;Journal for ImmunoTherapy of Cancer;2023-11

5. Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer;Signal Transduction and Targeted Therapy;2023-10-20